Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Turcot syndrome × XELOX × 1 year × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 5 Stomach Neoplasms 4 Rectal Neoplasms 4 Colonic Neoplasms 2 Turcot syndrome 1 Neoplasm Metastasis 1 Locally Advanced Rectal Cancer (LARC) 1 Locally Advanced Colorectal Cancer 1 Gastric Cancer Stage 1 Adenocarcinoma of the Lower Rectum 1

Interventions

pembrolizumab 8 Nivolumab 6 Ipilimumab 3 durvalumab 2 atezolizumab 2 Specimen Handling 2 toripalimab 1 relatlimab 1 fludarabine phosphate 1 fludarabine 1 danvatirsen 1 camrelizumab 1 avelumab 1 XELOX 1 Surgical Procedures, Operative 1 Neoadjuvant Therapy 1 Magnetic Resonance Spectroscopy 1 Irinotecan 1 Interleukin-2 1 Induction Chemotherapy 1 Immunotherapy 1 Immunoglobulin G 1 Immune Checkpoint Inhibitors 1 IMM-101 1 Docetaxel 1 Disulfides 1 Diffusion Tensor Imaging 1 DEAE-Dextran 1 Cyclophosphamide 1 Colonoscopy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07266025 2026-01-27

CATALIS

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting

Turcot syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡